1. Home
  2. AXDX vs SABS Comparison

AXDX vs SABS Comparison

Compare AXDX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AXDX
  • SABS
  • Stock Information
  • Founded
  • AXDX 1982
  • SABS 2014
  • Country
  • AXDX United States
  • SABS United States
  • Employees
  • AXDX N/A
  • SABS N/A
  • Industry
  • AXDX Biotechnology: Laboratory Analytical Instruments
  • SABS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AXDX Industrials
  • SABS Health Care
  • Exchange
  • AXDX Nasdaq
  • SABS Nasdaq
  • Market Cap
  • AXDX 13.7M
  • SABS 15.8M
  • IPO Year
  • AXDX 1996
  • SABS N/A
  • Fundamental
  • Price
  • AXDX $0.03
  • SABS $1.96
  • Analyst Decision
  • AXDX
  • SABS Strong Buy
  • Analyst Count
  • AXDX 0
  • SABS 6
  • Target Price
  • AXDX N/A
  • SABS $11.17
  • AVG Volume (30 Days)
  • AXDX 2.5M
  • SABS 42.7K
  • Earning Date
  • AXDX 05-20-2025
  • SABS 05-27-2025
  • Dividend Yield
  • AXDX N/A
  • SABS N/A
  • EPS Growth
  • AXDX N/A
  • SABS N/A
  • EPS
  • AXDX N/A
  • SABS N/A
  • Revenue
  • AXDX $11,698,000.00
  • SABS $377,835.00
  • Revenue This Year
  • AXDX $7.25
  • SABS N/A
  • Revenue Next Year
  • AXDX N/A
  • SABS $50.00
  • P/E Ratio
  • AXDX N/A
  • SABS N/A
  • Revenue Growth
  • AXDX N/A
  • SABS N/A
  • 52 Week Low
  • AXDX $0.12
  • SABS $1.00
  • 52 Week High
  • AXDX $2.09
  • SABS $5.01
  • Technical
  • Relative Strength Index (RSI)
  • AXDX 13.15
  • SABS 62.15
  • Support Level
  • AXDX $0.12
  • SABS $1.76
  • Resistance Level
  • AXDX $0.56
  • SABS $2.03
  • Average True Range (ATR)
  • AXDX 0.05
  • SABS 0.17
  • MACD
  • AXDX -0.04
  • SABS 0.03
  • Stochastic Oscillator
  • AXDX 0.00
  • SABS 59.68

About AXDX Accelerate Diagnostics Inc.

Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: